The most conventional way for ICB is to block the cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death receptor-1/programmed death ligand-1 (PD-1/PDL-1) pathways, which can reactivate tumor-suppressed immune cells [39]. This evidence concerns the gene CD274 and neoplasm.